INTRODUCTION

Although attempts to correlate the breadth of the CTL antiviral response and control of HIV-1 infection in vivo have been equivocal [1,2,3,4,5,6,7,8,9], accumulating evidence support the beneficial role of Gag-specific CTL responses in HIV-1 containment [2,10,11,12,13,14,15,16,17,18]. Allowing to differences in antiviral efficacy among specific CD8\(^+\) T-cell responses. Additionally, certain HLA genes are associated with different rates of disease progression [19,20,21,22,23,24,25,26,27,28,29]. In particular, HLA alleles B*27 and B*57 seem to confer a survival benefit whereas HLA B*35, B*40 confers a survival disadvantage [22]. While HLA-B alleles appear to impact disease progression more than other alleles [25], possessing heterologous HLA alleles, and thus possibly allowing the individual to present broader arrays of epitopes, has also been associated with delayed/slower disease progression [24].

The extent of polymorphisms in HIV sequences and in HLA loci underscores that a vast array of HLA/viral peptide combinations can be generated during infection. HIV-1 is characterized by its extensive diversity both among and within infected individuals due to its extreme capacity to mutate, its persistent replication, and the important role of CD8\(^+\) lymphocyte responses in driving viral evolution [30,31,32]. In addition, the HLA region is one of the most polymorphic loci in the human genome. HLA class I molecules are codominantly expressed on antigen-presenting cells such that all six allotypes (if the person expresses heterologous HLA-A, B and C proteins) can present viral epitopes. The fine-mapping of epitopes, typically 9 amino acid (AA) long but ranging from 8 to 11 AA, together with data on their binding properties to HLA molecules, has allowed definition of HLA class I allele-specific sequence motifs that are able to prime virus-specific CD8\(^+\) T-cell responses. Consistent associations between HLA alleles and disease outcomes suggest an underlying mechanistic function, and prompted us to question whether the scope of the epitope repertoire contributes to the composite effectiveness of the CTL response. “Epitope repertoire” here refers to all viral peptide sequences that fulfill HLA class I allele-specific binding motifs for a specific whole HIV-1 proteome.

Epitope mapping data has been used to develop computational methods of epitope prediction, which are important for the development of diagnostic tools and the design and evaluation of vaccines. Identification of novel HIV-1 epitopes simultaneously fuels our greater understanding of the immune recognition of the HIV proteome and incremental improvements of epitope prediction algorithms [33,34,35,36]. Here, we predicted HLA
class I epitopes using a new method based on logistic regression and designed to leverage data across HLA alleles and/or supertypes ([37] available at http://atom.research.microsoft.com/hlabinding/hlabinding.aspx). The prediction method produces approximately 10% false positive results when set to yield 10% false negatives.

We predicted the epitope repertoire in 302 full-length HIV-1 proteomes, isolated from 302 untreated individuals infected with HIV-1 subtypes C and B, based on each subject’s HLA genotype [32,38,39,40,41,42,43,44]. We report that a larger epitope repertoire was associated with lower levels of viremia. Furthermore, alleles associated with reduced viral loads tended to target particularly Gag when compared to alleles associated with a lack of control of viral replication.

RESULTS

The size of the epitope repertoire differed between HLA alleles and thereby between autologous HIV-1 proteomes

Scanning 302 HIV-1 proteomes, corresponding to 2,718 HIV-1 protein sequences, resulted in the identification of 22,779 epitope motifs, including 8,208 experimentally defined CTL epitopes compiled in databases prior to our study (the latter two figures include redundancies from detection of the same epitopes in multiple individuals). The number of predicted epitopes varied greatly among alleles, i.e., between 1 and 47 per allele per proteome, and henceforth among individuals ranging between 14 and 186 per proteome (mean = 75; median = 72). Given that the vast majority of known epitopes were defined experimentally using peptides corresponding to subtype B, more CTL epitopes are known for subtype B than for subtype C. Thus in turn, more motifs were identified in proteomes from subtype B (mean = 113 per proteome, including 60 previously known epitopes) than in subtype C (mean = 71, including 23 previously known epitopes). To rule out this experimental bias toward HIV-1 subtype B in our study, we verified that the number of epitopes restricted by an allele was not associated with the allele frequency in the population. There were no associations between the number of epitopes restricted by an allele and its frequency in the population in a subgroup of 32 individuals from the Seattle Primary Infection Cohort ($\chi^2 = 0.0280; p = 0.2307$), nor in a subtype C infected South African cohort from Durban ($\chi^2 = 0.0347; p = 0.1998$; n = 270 individuals) or in a representative Sub-Saharan population ($\chi^2 = 0.0319; p = 0.2197$). However, there was a positive relationship between the number of epitopes and the allele frequency in the overall North American population ($\chi^2 = 0.1153; p = 0.0129$; n = 1021 individuals), likely reflecting the focus of HIV/AIDS research on this population. Interestingly, HLA B*27, an allele repeatedly associated with favorable disease outcomes [22] and found 3 times in our dataset, presented the third largest epitope repertoire with 42 predicted epitopes per HIV-1 proteome, i.e., over 3 times the average repertoire size (Mean number of epitopes/HLA allele = 13.87; Confidence Interval (CI) with $\alpha = 0.99$, Lower CI = 9.46; Upper CI = 18.27).

Relationship between epitope repertoires and clinical data

We compared numbers of predicted epitopes per proteome to viral loads and CD4 counts in subtype C infected individuals from the South African cohort. We found that the more epitopes predicted for an individual, the lower the observed viral load ($\chi^2 = 0.0446$, $p = 0.0005$; Spearman’s correlation factor: $Rho = -0.1751$, $p = 0.0039$). In particular, we found a stronger negative relationship between the size of the epitope repertoire and the viral loads among the 81 individuals who had CD4 counts above 400, i.e., when we excluded from the analysis the individuals with vanishing T cell numbers, and presumably function ($\chi^2 = 0.1069, p = 0.0038$; Spearman’s correlation factor: $Rho = -0.3090, p = 0.0050$) (Figure 1A). Additionally, larger epitope repertoires were associated with higher CD4 counts ($\chi^2 = 0.0620, p = 0.0250$; Spearman’s $Rho = 0.1549, p = 0.0395$) (Figure 1B). A relatively weaker association was observed for CD4 than for viral loads, possibly due to CD4 counts being available for only 177 of the 270 individuals evaluated.

By grouping individuals according to their plasma viral loads, we found significantly different numbers of predicted HIV-1 epitopes in individuals within the lowest (<16,437 viral RNA copies/ml; n = 67) and highest (>186,250 copies; n = 67) quartiles. HIV-1 proteomes from individuals in the quartile with the lowest viral load had a mean number of 80 predicted epitopes, compared to 67 in the highest quartile ($p = 0.0047$) (Figure 1C). There was also a trend for individuals with higher CD4 counts to have more predicted epitopes, the mean number was 76 for individuals in the highest quartile (n = 45; CD4>521.5), and 65 in the lowest quartile (n = 44; CD4<234.5) ($p = 0.0686$).

The least frequent alleles in the cohort were found to be associated with lower viral loads (Spearman’s $Rho = 0.2880; p = 0.0448$), in agreement with Trachtenberg and colleagues [21]. And, we found a trend indicating that HLA alleles restricting larger repertoires were associated with lower viral loads in HLA-matched individuals (Figure 1D) (Spearman’s $Rho = -0.2952; p = 0.0517$).

Distribution of epitope repertoires vary between HLA alleles associated with different viral loads

Next, we ranked HLA alleles by the average viral loads of subjects in the Durban cohort: the quartile with the lowest viral loads (<125,437 viral copies; mean = 65,384; median = 58,229) included 12 alleles, herein referred as “good” alleles; the quartile with the highest viral loads (>320,643 viral copies; mean = 971,587; median = 351,20) included 12 “bad” alleles. Interestingly, the distribution of predicted epitopes among HIV-1 proteins revealed that “good” HLA alleles focused more on Gag (Figure 2A) and less on Nef (Figure 2B). For “good” HLA alleles, predicted Gag epitopes increased 1.69 fold ($p = 0.036$) compared to the distribution found for “bad” HLA alleles, while predicted Nef epitopes decreased 2.35 fold ($p = 0.038$). When analyzed by individual protein, Gag- and Rev-specific repertoire showed more epitopes restricted by “good” HLA alleles than by “bad” ones, whereas there were more epitopes restricted by “bad” HLA alleles than by “good” ones in Nef, Env, Pol, Tat, Vif, Vpu, and also Vpr (albeit marginally) (Figure 2C). Nef- and Gag-specific epitope repertoires showed similar percentages of epitopes restricted by “good” alleles, however, the proportion of epitopes restricted by “bad” alleles was significantly higher in Nef compared to its proportion in Gag.

DISCUSSION

We systematically examined the immunogenic potential of HIV-1 at the population level through in silico estimation of the epitope repertoire of 302 HIV-1 proteomes. The number of predicted HIV-1 epitopes per proteome varied considerably between HLA alleles and thereby among individuals. Additionally, there were more epitopes identified in subtype B viruses than in subtype C, reflecting the existing bias of databases for inclusion of data from...
subtype B viruses and subtype B-infected individuals. Importantly, while we demonstrated that our analysis was not confounded by this experimental bias, it also highlights the need for better characterization of CTL responses against HIV-1 subtype C in the affected population (i.e., with typical motifs and HLA allele restrictions). Nonetheless, limitations to epitope prediction analyses intrinsically include biases derived from their training datasets, the fact that certain epitopes are not optimally defined or have incorrect HLA alleles restrictions (e.g., due to linkage disequilibrium) and pervasive of HLA class I allele promiscuity [45]. Despite those potential shortcomings, our findings corroborate those from immunological studies in this cohort. Principally, individuals with high viral loads tended to target preferentially Env and Accessory/Regulatory proteins [18,27,44,46], while individuals with low viral loads tended to make strong CTL responses against Gag [18,27,44,46]. Additionally, by comparison with subtype B infected individuals Frahm and colleagues showed the importance of subdominant CTL responses for the control of replication in subtype C infected individuals [18,27,44,46]. Collectively, those studies lend support to our in silico approach, especially in the context of a relatively limited knowledge of CTL responses in HIV-1 subtype C infection.

We also explored whether specificities of the epitope repertoires could affect clinical markers of disease progression. By integrating HIV-1 proteome-wide epitope mining to clinical and laboratory data in a South African cohort, our data showed a trend indicating that the number of HLA/epitope pairs was correlated both negatively with viral loads and positively with CD4 counts. Hence, HLA alleles associated with lower viral load in this cohort, referred to as “good” alleles, tended to present larger predicted epitope repertoires than HLA alleles associated with high viremias, the “bad” alleles. This suggests that the inherent ability to present more epitopes could be a contributing factor to better clinical disease status. Alternatively, certain sets of epitopes may be needed to control the infection and thus, the more epitope motifs presented, the more likely individuals are to cover those epitopes. Our data alludes to a mechanistic paradigm in the cell-mediated immune response, supporting the intuitive assertion that control of HIV infection would capitalize on a broad repertoire while control would be stymied by a narrower epitopic pool. However, a nettlesome HIV characteristic is that despite eliciting relatively broad CTL responses, this generally does not result in the containment of the virus. Although attempts to correlate the breadth of the CTL antiviral response and control of HIV-1 infection in vivo have been equivocal [1,2,3,4,5,6,7,8,9,18], it could nonetheless be beneficial for the host to have a larger epitopic pool to choose from – maybe not as a means to broaden the CTL response but rather to increase the probability of producing the more limited, effective set of CTL responses, since a diverse panoply of epitopes can be available for CTL recognition simultaneously and/or successively.

Figure 1. HIV-1 epitope repertoires and clinical data. Putative epitopes were identified in silico within full-length autologous HIV-1 proteomes and combined with previously described optimally defined CTL epitopes found in the LANL and IEDB databases. (A) and (B) respectively show the log viral loads and the CD4 counts plotted as a function of the number of predicted HIV-1 epitopes identified per proteome for the individuals with CD4 counts above 400 (n = 81). (C) Shows the number of predicted HIV-1 epitopes for individuals belonging to the highest (mean = 65) and lowest (mean = 76) viremia quartile. (D) Shows the average viral loads of individuals presenting a specific allele as a function of the average number of HIV-1 predicted epitopes for that allele (only alleles presented by at least 3 individuals in the South-African cohort were included).

doi:10.1371/journal.pone.0001424.g001

HIV-1 Epitope Repertoire

PLoS ONE | www.plosone.org 3 January 2008 | Issue 1 | e1424
While the efficacy of the CTL response does not appear to rely solely on its breadth, it is widely believed that CTL escape has a major impact on disease outcome. As such, the limited epitope repertoire we identified for individuals/alleles associated with high viremia could reflect escape mutations that eliminated binding motifs from the autologous viral sequences.

In addition to quantitative distinctions, there were also qualitative differences between epitope repertoires restricted by specific HLA alleles: Those associated with better control of HIV replication were likely to present more Gag epitopes in their repertoire than "bad" alleles did; "bad" alleles were instead associated with a higher proportion of Nef epitopes. Interestingly, a recent study by Kiepiela and colleagues showed that Nef-specific CTL responses were associated with higher viral loads, unlike Gag-specific CTL responses, which were associated with lower viral burdens [2,44]. While numerous reports have emphasized that CTL responses targeting Gag are the most tightly associated with the control of HIV replication [2,10,11,12,13,14,15,16,17], little is known about the underlying mechanism. Our study indicates that "good" alleles preferentially target Gag, and that within Gag there is an over-representation of epitopes restricted by "good" alleles instead of "bad" ones, as seen for all other HIV-1 proteins (except Rev). Interestingly, our results using clinical and laboratory data from infected individuals agrees with a very recent in silico study showing that HLA alleles with a low Relative Hazard (RH) of disease progression preferentially presented p24 epitopes [47]. Thus, discordant viral loads depending on specific protein targeting are apparently associated with particular HLA allele restriction sets for each protein. Nonetheless, this leaves open the question of what accounts for the beneficial effect on viremia: CTL responses focusing specifically on Gag, or CTL responses restricted by certain "good" alleles, or both.

The potential shortcomings of in silico epitope predictions cannot be entirely dismissed. And, notwithstanding the composite aspect of the cell-mediated immune response and the difficulty in ascertaining the relative importance of each attribute, evidence that the CTL response is in part mechanically predetermined could be significant in on-going efforts to define more palatable criteria of the immune response to assist vaccine design. Our findings are therefore relevant for vaccine design as they suggest
the need to 1) maximize the number of possible epitopes to include in
a vaccine candidate and to 2) direct the immune response
toward Gag rather than Nef proteins [44,48,49].

MATERIALS AND METHODS
Dataset
We evaluated 302 HIV-1 full-length plasma-derived genome sequences along with the HLA genotypes of the infected individuals. 270 subjects were from Durban (South Africa) infected with HIV-1 subtype C [38,39] and 32 subjects from the Seattle PIC cohort (USA) [43] infected with HIV-1 subtype B [32,40,41,42] (and unpublished). Immunological and clinical data (viral loads and CD4 counts) were available at the time of virus sampling for a subgroup of the Durban cohort; details were described elsewhere [44]. HIV-1 amino acid sequences were derived for all recognized protein coding sequences of the 302 HIV-1 genomes. HLA allele

Epitope Prediction
We employed an implementation of our previously described model [37] that uses logistic regression and leverages data across HLA alleles to predict CTL epitopes (http://atom.research. ncbi.nlm.nih.gov/projects/mhc/ihwg.cgi?cmd = PRJOV&ID = 9.

We employed an implementation of our previously described model [37] that uses logistic regression and leverages data across HLA alleles to predict CTL epitopes (http://atom.research. ncbi.nlm.nih.gov/projects/mhc/ihwg.cgi?cmd = PRJOV&ID = 9.

We employed an implementation of our previously described model [37] that uses logistic regression and leverages data across HLA alleles to predict CTL epitopes (http://atom.research. ncbi.nlm.nih.gov/projects/mhc/ihwg.cgi?cmd = PRJOV&ID = 9.

REFERENCES
1. Frahm N, Korber BT, Adams CM, Szniger JJ, Draenert R, et al. (2004) Consistent cytotoxic-T-lymphocyte targeting of immunodominant regions in human immunodeficiency virus across multiple ethnicities. J Virol 78: 2167–2200.
2. Zuniga R, Luschetti A, Galvan P, Sanchez S, Sanchez C, et al. (2006) Relative dominance of Gag p24-specific cytotoxic T lymphocytes is associated with human immunodeficiency virus control. J Virol 80: 3121–3125.
3. Masemola A, Mashashi T, Khoasy G, Molube P, Mokgoro P, et al. (2004) Hierarchical targeting of subtype C human immunodeficiency virus type 1 proteins by CD8+ T cells: correlation with viral load. J Virol 78: 3233–3243.
4. Gea-Banacloche JC, Miguel S, Martinez D, Unt B, McNeil AC, et al. (2000) Maintenance of large numbers of virus-specific CD8+ T cells in HIV-infected progressed and long-term non-progressors. J Immunol 165: 1892–1902.
5. Edwards BH, Bansal A, Sabbaj S, Bakari J, Mulligan MJ, et al. (2002) Magnitude of functional CD8+ T-cell responses to the gag protein of the human immunodeficiency virus type 1 correlates inversely with viral load in plasma. J Virol 76: 2298–2305.
6. Betts MR, Ambrosoli DR, Douek DC, Bonhoeffer S, Benchley JM, et al. (2001) Analysis of total human immunodeficiency virus (HIV)-specific CD4+ and CD8+ T-cell responses: relationship to viral load in untreated HIV infection. J Virol 75: 11983–11991.
7. Addo MM, Yu XG, Rahsd A, Cohen D, Elderlidge RL, et al. (2003) Comprehensive epitope analysis of human immunodeficiency virus type 1 (HIV-1)-specific T-cell responses directed against the entire expressed HIV-1 genome demonstrate broadly directed responses, but no correlation to viral load. J Virol 77: 2081–2092.
8. Macey L, Hughes J, Schacher T, Shea T, Corey L, et al. (1997) Cytoxic-T-cell responses, viral load, and disease progression in early human immunodeficiency virus type 1 infection. N Engl J Med 337: 1267–1274.
9. Liu Y, McNeil J, Zhao H, Treit DM, McSwain M, et al. (2007) Evolution of HIV-1 CTL epitope: Fitness-Balanced Escape. ePub.
10. Novitsky V, Gilbert P, Peter T, McLane M, Fauci A, et al. (2003) Association between virus-specific T-cell responses and plasma viral load in human immunodeficiency virus type 1 subtype C infection. J Virol 77: 842–890.
11. Oggi GS, Jin X, Bonhoeffer S, Dabora PR, Nowak MA, et al. (1998) Quantitation of HIV-1-specific T lymphocytes and plasma viral load of viral RNA. Science 279: 2103–2106.
12. Riviere Y, McChesney MB, Porret F, Tanneau-Salvador F, Sanonetti P, et al. (1993) Gag-specific cytotoxic responses to HIV type 1 are associated with a decreased risk of progression to AIDS-related complex or AIDS. AIDS Res Hum Retroviruses 11: 903–907.
13. Geldmacher C, Currier JR, Herrmann E, Haule A, Kuta E, et al. (2007) CD8 T-cell recognition of multiple epitopes within specific Gag regions is associated with maintenance of a low steady-state viremia in human immunodeficiency virus type 1-seropositive patients. J Virol 81: 2440–2448.
14. Sacha JB, Chung C, Rakasz EG, Spencer SP, Jonas AK, et al. (2007) Gag-specific CD8+ T lymphocytes recognize infected cells before AIDS-virus integration and viral protein expression. J Immunol 178: 2746–2754.
15. Ramduth D, Petty A, Mugganavan GC, Neun N, Harlow JD, et al. (2005) Differential immunogenicity of HIV-1 clade C proteins in eliciting CD8+ and CD4+ cell responses. J Infect Dis 192: 1561–1566.
16. Crawford H, Prado JG, Leslie A, Hoe S, Honeyborne I, et al. (2007) Compensatory Mutation Partially Restores Fitness and Delays Reversion of Escape Mutation within the Immunodominant Hla-B*5703-Restricted Gag Epitope in Chronic HIV-1 Infection. J Virol.
17. Streeck H, Schneirhardt B, Jensen H, Allgaeier KJ, Wrin T, et al. (2007) Loss of HIV-1-specific T-cell responses associated with very rapid HIV-1 disease progression. AIDS 21: 889–891.
18. Honeyborne I, Prendergast A, Perera F, Leslie A, Crawford H, et al. (2007) Control of human immunodeficiency virus type 1 is associated with HLA-B*13 and targeting of multiple gag-specific CD8+ T-cell epitopes. J Virol 81: 3667–3672.
19. Carrington M, O’Brien SJ (2003) The influence of HLA genotype on AIDS. Annu Rev Med 54: 533–551.
20. Migueles SA, Sabigham NY, Szipert WL, Bettinotti MP, Maricome LM, et al. (2009) HLA B*5701 is highly associated with restriction of virus replication in a subgroup of HIV-infected long term nonprogressors. Proc Natl Acad Sci U S A 97: 2709–2714.
21. Trachtenberg E, Korber B, Sollars C, Kepler TB, Hraber PR, et al. (2003) Advantage of rare HLA supertype in HIV disease progression. Nat Med 9: 929–935.
22. O’Brien SJ, Gao X, Carrington M (2001) AIDS and AIDS: a cautionary tale. Trends Mol Med 7: 379–381.
23. Gao X, Nelson GW, Karacki P, Martin MP, Phair J, et al. (2001) Effect of a single amino acid change in MHC class I molecules on the rate of progression to AIDS. N Engl J Med 344: 1668–1673.
24. Carrington M, Nelson GW, Martin MP, Kissner T, Vlahov D, et al. (1999) HLA and HIV-1: heterozygote advantage and B*57-Cw*04 disadvantage [see comments]. Science 285: 1748–1752.
25. Kielpia P, Leslie AJ, Honeyborne I, Ramduth D, Thobakgale C, et al. (2004) Dominant influence of HLA-B in mediating the potential co-evolution of HIV and HLA. Nature 432: 769–775.
26. Frahm N, Adams S, Kielpia P, Linder EH, Hewitt HS, et al. (2003) HLA-B*57 presents HLA-B*57-restricted cytotoxic T lymphocyte epitopes and is associated with low human immunodeficiency virus infection. J Virol 79: 10218–10225.

Acknowledgments
We thank Brian Birditt and Brandon S. Maust for help with data gathering, and Dr. Joshua T. Herbeck for valuable discussions and critical reading of the manuscript.

Author Contributions
Conceived and designed the experiments: MR. Performed the experiments: HC DH WD KB. Analyzed the data: CB JM DH MR CR. Contributed reagents/materials/analysis tools: PG BW CB HC CR KB. Wrote the paper: PG BW JM DH MR.
27. Frahm N, Kiepiela P, Adams S, Linde CH, Hewitt HS, et al. (2006) Control of human immunodeficiency virus replication by cytotoxic T lymphocytes targeting subdominant epitopes. Nat Immunol 7: 173–178.

28. MacDonald KS, Embree JE, Nagelkerke NJ, Castille J, Ramhadin S, et al. (2001) The HLA A2/6802 supertype is associated with reduced risk of perinatal human immunodeficiency virus type 1 transmission. J Infect Dis 183: 503–506.

29. MacDonald KS, Fowke KR, Kimani J, Dunand VA, Nagelkerke NJ, et al. (2000) Influence of HLA supertypes on susceptibility and resistance to human immunodeficiency virus type 1 infection. J Infect Dis 181: 1581–1589.

30. Jones NA, Wei X, Flower DR, Wong M, Michor F, et al. (2004) Determinants of human immunodeficiency virus type 1 escape from the primary CD8+ cytotoxic T lymphocyte response. J Exp Med 200: 1243–1256.

31. Allen TM, Alföldi M, Geer SC, Kalife ET, Moore C, et al. (2005) Selective escape from CD8+ T-cell responses represents a major driving force of human immunodeficiency virus type 1 (HIV-1) sequence diversity and reveals constraints on HIV-1 evolution. J Virol 79: 13239–13249.

32. Liu Y, McNevin J, Cao J, Zhao H, Genowatti I, et al. (2006) Selection on the human immunodeficiency virus type 1 proteome following primary infection. J Virol 80: 9519–9529.

33. Suhrbier A, Schmidt C, Fernan A (1993) Prediction of an HLA B8-restricted influenza epitope by motif. Immunology 79: 171–173.

34. Larsen MV, Lundegaard C, Lamberth K, Buus S, Brunak S, et al. (2005) An integrative approach to CTL epitope prediction: a combined algorithm integrating MHC class I binding, TAP transport efficiency, and proteasomal cleavage predictions. Eur J Immunol 35: 2295–2303.

35. Lundegaard C, Nielsen M, Lund O (2006) The validity of predicted T-cell epitopes. Trends Biotechnol 24: 537–538.

36. Louzoun Y, Vider T, Weigert M (2006) T-cell epitope repertoire as predicted from human and viral genomes. Mol Immunol 43: 559–569.

37. Heckerman D, Kadie C, Listgarten J (2006) Leveraging information across HLA alleles/supertypes improves epitope prediction. Tenth Annual International Conference on Research in Computational Molecular Biology (RECOMB), Venice, Italy.

38. Rousseau CM, Learn GH, Mullins JI (2007) A new, core elements approach to vaccine immunogen design. PLoS Pathogens: In press.

39. Rolland M, Nickle DC, Mullins JI (2007) Extensive HLA class I allele promiscuity among viral CTL epitopes. Eur J Immunol 37: 2499–2508.

40. Rolland M, Nickle DC, Mullins JI (2007) Extensive HLA class I allele promiscuity among viral CTL epitopes. Eur J Immunol 37: 2499–2508.

41. Tufferey D, Park DH, Casasnovas O, Faull R, McGeoch D, et al. (2007) HIV-1 proteome as predicted from human and viral genomes. PLoS Comput Biol 3: e60.

42. Korber BTM, Brander C, Haynes BF, Koup R, Moore JP, et al. (2002) HIV Molecular Immunology. Los Alamos National Laboratory, Theoretical Biology and Biophysics, Los Alamos, New Mexico. LA-UR-02-036.

43. Wu CH, Apweiler R, Bairoch A, Natale DA, Barker WC, et al. (2006) The Universal Protein Resource (UniProt): an expanding universe of protein information. Nucleic Acids Res 34: D167–191.